GlassScriptPhysician profile
Kenneth Brian King
NPI 1750469680
$39,078.25
in general payments reported to CMS, 2019-2025
28 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $483 · 2021: $1,418 · 2022: $2,119 · 2023: $2,452 · 2024: $14K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Food and Beverage: $10K · Consulting Fee: $3,875 · Travel and Lodging: $3,158 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $17,200.00 |
| Food and Beverage | $10,156.29 |
| Consulting Fee | $3,875.00 |
| Travel and Lodging | $3,158.32 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $22,641.21 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Rxsight INC | $6,197.50 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $1,477.60 | 2019-2025 | Cequa |
| Abbvie INC. | $1,200.23 | 2022-2025 | |
| Glaukos Corporation | $1,017.52 | 2022-2025 | Idosetr, Idose, Radius Xr |
| Biotissue Holdings INC. | $924.01 | 2021-2025 | |
| Alcon Vision LLC | $777.93 | 2022-2025 | Tryptyr, Rocklatan, Eysuvis |
| Allergan, INC. | $680.10 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $550.64 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $484.75 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $426.65 | 2019-2023 | Tecnis Iol, Veritas Vision System |
| Kala Pharmaceuticals, INC. | $361.75 | 2020-2022 | |
| Lensar, INC. | $317.36 | 2020-2024 | Lensar Laser System |
| Harrow Eye, LLC | $301.62 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $252.27 | 2019-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $247.58 | 2022-2025 | Tyrvaya, Ryzumvi |
| Carl Zeiss Meditec USA, INC. | $239.61 | 2022-2024 | Cirrus Hd-Oct, Artevo 800, Humphrey Hfa |
| Shire North American Group INC | $221.57 | 2019 | |
| Dompe US, INC. | $201.58 | 2023-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $144.36 | 2019-2021 | |
| Astellas Pharma US INC | $107.11 | 2023 | |
| Aerie Pharmaceuticals, INC. | $106.62 | 2020-2021 | |
| Thea Pharma INC. | $72.24 | 2023-2024 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $58.34 | 2019-2021 | |
| Ocular Therapeutix, INC. | $22.00 | 2021 | |
| Omeros Corporation | $19.64 | 2021 | |
| Optos, INC. | $16.04 | 2021 | |
| Tearlab Corp | $10.42 | 2023 | Tearlab Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.